Lifeboat Foundation

Great news for Repair Biotechnologies a new startup company developing solutions to age-related immune system decline and heart disease.

In 2018, Reason and Bill Cherman founded Repair Biotechnologies, which, as its name suggests, is a rejuvenation biotechnology company focused on damage repair approaches to aging. The company has recently completed a seed round of investment funding, with a total of $2.15 million being put into the company’s coffers to bolster research and development. Reason described this seed round as follows:

We are very pleased to have the support of noted investors such as Jim Mellon. They are the people who are presently providing the fuel and publicity for ever faster progress in the longevity biotechnology industry.

Continue reading “Repair Biotechnologies Raises a $2.15M Seed Round” »

We’re tantalizingly close to growing organs in the lab, but the biggest remaining challenge has been creating the fine networks of blood vessels required to keep them alive. Now researchers have shown that a common food dye could solve the problem.

In the US there are currently more than 100,000 people on organ transplant waiting lists. Even if you’re lucky enough to receive a replacement, you face a lifetime on immunosuppressant drugs. That’s why scientists have long dreamed of growing new organs from patients’ own cells, which could simultaneously tackle the shortage and the risk of organ rejection.

The field of tissue engineering has seen plenty of progress. Lab-grown skin has been medically available for decades, and more recently stem cells have been used to seed scaffolds—either built form synthetic materials or made by stripping cells from natural support structures—to reproduce more complex biological tissue.

Continue reading “New Progress in the Biggest Challenge With 3D Printed Organs” »

One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to one of Wall Street’s major investment banks.

Michigan State University senior vice president Stephen Hsu, a theoretical physicist and the founder of Genomic Prediction, demonstrates how the machine learning revolution, combined with the dramatic fall in the cost of human genome sequencing, is driving a transformation in our relationship with our genes. Stephen and Azeem Azhar explore how the technology works, what predictions can and cannot yet be made (and why), and the ethical challenges created by this technology.

In this podcast, Azeem and Stephen also discuss:

Graphene underwear.

L(170÷95) Waist circumference65 leg circumference21.

XL（175/100）Waist circumference 69 leg circumference 23.

Continue reading “VO Underwear S8 Graphene air Pants Trace Antibacterial Blood Circulation Briefs(2-Pack)” »

Cardiovascular disease is a major cause of death worldwide, and treating it isn’t easy. The disease wreaks havoc on patients’ blood vessels and can require complex bypass surgery.

Scientists at the Morgridge Institute for Research are working toward a dream of creating artery banks—similar to blood banks common today—with readily-available material to replace diseased arteries during surgery.

The latest work in the lab of Morgridge regenerative biologist James Thomson puts the science one step closer to that goal.

Continue reading “Stem cell scientists clear another hurdle in creating transplant arteries” »

Most antibiotics work by interfering with critical functions such as DNA replication or construction of the bacterial cell wall. However, these mechanisms represent only part of the full picture of how antibiotics act.

In a new study of antibiotic action, MIT researchers developed a new machine-learning approach to discover an additional mechanism that helps some antibiotics kill bacteria. This secondary mechanism involves activating the bacterial metabolism of nucleotides that the cells need to replicate their DNA.

“There are dramatic energy demands placed on the cell as a result of the drug stress. These energy demands require a metabolic response, and some of the metabolic byproducts are toxic and help contribute to killing the cells,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering, and the senior author of the study.

Continue reading “Machine learning reveals metabolic pathways disrupted by the drugs, offering new targets to combat resistance” »

Newly identified subsets of cell types present in joint tissue in people with rheumatoid arthritis and how they interact may explain why only some people respond to existing medications, according to two studies by co-senior author Laura Donlin, Ph.D., Co-Director of the Derfner Foundation Precision Medicine Laboratory at Hospital for Special Surgery (HSS) and collaborating colleagues. The findings suggest exciting new targets for developing precision medicine strategies in the future.

Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints. The immune system mistakenly perceives joint tissue as a harmful invader, like a bacteria or virus, and attacks it, causing inflammation, pain and swelling. RA affects an estimated 1.3 million Americans, about 1% of the population. Critical unmet needs in RA treatment are medications that effectively treat all people with RA, especially those who do not respond to disease-modifying antirheumatic drugs (DMARDs) or biologics.

RA involves a complex interplay between many different types of cells—including T cells, B cells, monocytes and fibroblasts—but the specific subtypes that drive disease progression are largely undefined. Understanding these cell types more precisely may hold valuable information in developing new treatments.

Continue reading “Researchers advance understandings of the cellular mechanisms driving rheumatoid arthritis” »

Deep brain stimulation (DBS), an experimental technology that involves implanting a pacemaker-like device in a patient’s brain to send electrical impulses, is a hotly debated subject in the field of medicine. It’s an inherently risky procedure and the exact effects on the human brain aren’t yet fully understood.

But some practitioners believe it could be a way to alleviate the symptoms of depression or even help treat Alzheimer’s — and now they suspect it could help with drug addiction as well.

In a world’s first, according to the Associated Press, a patient in Shanghai’s Ruijin Hospital had a DBS device implanted in his brain to treat his addiction to methamphetamine.

Continue reading “In China, Surgeons Are Treating Addiction With Brain Implants” »